KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBT (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EBT for 13 consecutive years, with -$110.9 million as the latest value for Q4 2025.

  • Quarterly EBT fell 48.8% to -$110.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$351.1 million through Dec 2025, down 44.23% year-over-year, with the annual reading at -$351.1 million for FY2025, 44.23% down from the prior year.
  • EBT for Q4 2025 was -$110.9 million at Xenon Pharmaceuticals, down from -$90.2 million in the prior quarter.
  • The five-year high for EBT was $129.5 million in Q4 2023, with the low at -$110.9 million in Q4 2025.
  • Average EBT over 5 years is -$34.3 million, with a median of -$44.5 million recorded in 2023.
  • The sharpest move saw EBT tumbled 10332.71% in 2021, then surged 439.23% in 2022.
  • Over 5 years, EBT stood at -$25.1 million in 2021, then soared by 439.23% to $85.1 million in 2022, then skyrocketed by 52.26% to $129.5 million in 2023, then tumbled by 157.53% to -$74.5 million in 2024, then plummeted by 48.8% to -$110.9 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$110.9 million, -$90.2 million, and -$85.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.